Added to YB: 2026-07-01
Pitch date: 2026-06-29
BAYN.DE [neutral]
Bayer Aktiengesellschaft
+5.47%
current return
Author Info
Duck Pond Value Research is seeking tranquil ponds with a value philosophy. Margin of safety is not just a mantra. Follow us for investment theses, sector reports, or our economic perspectives. Sometimes ponds can be moats. Sign up for the newsletter.
Company Info
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
Market Cap
EUR 46.2B
Pitch Price
EUR 45.90
Price Target
N/A
Dividend
0.23%
EV/EBITDA
7.51
P/E
-21.42
EV/Sales
1.74
Sector
Pharmaceuticals
Category
special_situation
Bayer AG (ETR: BAYN) - Update
BAYN.DE (holding update): Roundup litigation nearing resolution—Feb 2026 $7.25B settlement proposal (matches author's ~$7B estimate) + June Supreme Court win neutralizing failure-to-warn doctrine pressures plaintiffs to settle. Pharma at inflection: Nubeqa/Kerendia offset Xarelto loss, 3 new approvals. Insiders bought €3M in 2026. SOTP value unlock thesis intact; H1 results Aug 4.
Read full article (4 min)